16 results on '"Best, Carlos"'
Search Results
2. Biological and Classical Prognostic Factors with Impact on Overall Survival in Patients with Early Stage (I/II) Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
3. Serum Albumin and Neutrophil-to-Lymphocyte Ratio, Two Independent Factor Predicting Survival in Patients with Follicular Lymphoma: A Multi-Institutional Retrospective Cohort of 741 FL, from the Latin American Lymphoproliferative Study Group (GELL)
4. Validating the Halp Score (Hemoglobin,Albumin, Lymphocytes, and Platelets) and the Neutrophil/Lymphocyte Ratio ( NLR) As Prognostic Factors for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. Retrospective Analysis By the Grupo De Estudio De Latino America De Linfoproliferativos (GELL)
5. A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL)
6. A Multi-Institutional Validation of the Prognostic and Predictive Value of the Neutrophil-to-Lymphocyte Ratio in Patients with Diffuse Large B- Cell Lymphoma: A Study from the Latin American Working Group for Lymphomas (GELL)
7. Assessment of Different Biological Variables (Serum Albumin, β-2-Microglobulin, Lymphocyte/Monocyte ratio, Neutrophil/Lymphocyte ratio, Platelet/Lymphocyte ratio) in a Retrospective Cohort of 525 Diffuse Large B-Cell Lymphomas As Predictor Factor(s) for Overall Survival
8. International Prognostic Indexes (IPI, RIPI, NCCN-IPI) for Predicting Overall Survival in Diffuse Large B-Cell Lymphoma Can be Improved By Adding Serum Albumin As Another Predictive Factor. Retrospective Study of the Mexican Study Group in Lymphoma from a Database of 855 Patients
9. "Ultrasensitive Reactive C-Protein As an Affordable Biomarker of Quantitative Expression of the BCR-ABL Transcript in Chronic Myeloid Leukemia. an Exploratory Study."
10. Imatinib Mesylate as First-line Therapy in Patients with Chronic Myeloid Leukemia Philadelphia + (CML-PH+) in Accelerated Phase (AP), Comparison with Chronic Phase. A Long Term Retrospective Study
11. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia philadelphia + (CML-PH+) in accelerated phase (AP), comparison with chronic phase. a long-term retrospective study.
12. Validating the HalpScore (Hemoglobin,Albumin, Lymphocytes, and Platelets) and the Neutrophil/Lymphocyte Ratio ( NLR) As Prognostic Factors for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. Retrospective Analysis By the Grupo De Estudio De Latino America De Linfoproliferativos (GELL)
13. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts
14. Mexican Guidelines for the Diagnosis and Treatment of Chronic Myeloid Leukaemia
15. The Age of Mexican Patients with Chronic Myeloid Leukemia (CML) Ph+ Is Quite Younger Than the Reported in USA and European Series.
16. Assessment of Different Biological Variables (Serum Albumin, ß-2-Microglobulin, Lymphocyte/Monocyte ratio, Neutrophil/Lymphocyte ratio, Platelet/Lymphocyte ratio) in a Retrospective Cohort of 525 Diffuse Large B-Cell Lymphomas As Predictor Factor(s) for Overall Survival
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.